Jodie Hay

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley et al. · The Lancet · 2021 · 649 citations · Full text

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews et al. · Nature Medicine · 2021 · 558 citations · Full text

Vaccination, Vaccine Development, Viral Burden +13

Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey

Koen B. Pouwels, Thomas House, Emma Pritchard et al. · The Lancet Public Health · 2020 · 208 citations · Full text

Virus Epidemiology, Emerging Infectious Diseases, Covid-19 Pandemic +8

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews et al. · 2021 · 144 citations · Full text

Immunology, Delta Variant, Covid-19 +17